AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

Contributed by: Business Wire

Logo

Tags

Health

Neurology

Genetics

Clinical Trials

Pharmaceutical

Biotechnology

AviadoBio

More Like This

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial

AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London

AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations